Durham, NC 的 肺癌 臨床試驗
32 項針對 肺癌 的研究正在 Durham（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Duke University, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Durham VA Medical Center, Durham
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
招募中3 期
- Duke Cancer Center, Durham
A Study of PHN-012 in Patients With Advanced Solid Tumors
招募中1 期
- PHN-012-001 Site, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
招募中3 期
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 距離 10 英里
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
招募中3 期
- Duke University Medical Center, Durham
Study of Trilaciclib and Lurbinectidin
招募中2 期
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill · 距離 10 英里
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
招募中2 期
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 距離 10 英里
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
招募中1/2 期
- Duke University School of Medicine, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
招募中2 期
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · 距離 10 英里
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 距離 10 英里
Health Education Approach to Lung Screening
招募中歡迎健康志工
- University of North Carolina-Chapel Hill, Carrboro · 距離 11 英里
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
招募中3 期
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
招募中1 期
- Xencor Investigative Site, Durham
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
招募中1/2 期
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 距離 10 英里
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
招募中
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 距離 10 英里
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
招募中2 期
- University of North Carolina, Chapel Hill · 距離 10 英里
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
招募中1 期
- Research Site, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
招募中1 期
- Duke Cancer Center, Durham
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
招募中1/2 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距離 10 英里
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Durham VA Medical Center, Durham
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
招募中歡迎健康志工
- Duke University, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
招募中
- Durham VA Medical Center, Durham, NC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
招募中1 期
- Duke Cancer Institute, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
招募中早期第 1 期
- Lineberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Chapel Hill · 距離 10 英里
UNC Pleural Fluid Registry
招募中觀察性研究
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill · 距離 10 英里
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
招募中2 期
- University of North Carolina, Chapel Hill · 距離 10 英里
其他城市的 肺癌 試驗
- Houston, TX78 項研究
- Boston, MA62 項研究
- New York City, NY60 項研究
- Los Angeles, CA45 項研究
- Arlington, VA41 項研究
- Washington, DC41 項研究
- Chicago, IL41 項研究
- Baltimore, MD40 項研究
- Nashville, TN40 項研究
- St. Louis, MO39 項研究
- Columbus, OH37 項研究
- Philadelphia, PA36 項研究
Durham 的其他研究
- 乳癌64 項研究
- 癌症（所有類型）58 項研究
- 非小細胞肺癌39 項研究
- 多發性骨髓瘤37 項研究
- 急性髓系白血病33 項研究
- 轉移性癌症33 項研究
- 前列腺癌32 項研究
- 大腸直腸癌28 項研究
- 卵巢癌27 項研究
- 慢性淋巴性白血病27 項研究
- 心臟衰竭26 項研究
- 胰臟癌24 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。